Valiant Organics Limited · NSE:VALIANTORG

Valiant Organics — Investor Presentation (July 2022)

29 slides from Valiant Organics's investor presentation, July 2022

  1. Slide 1: Valiant Organics Limited

    •••• Valiant Organics Limited Date: July 01,2022 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, "Exchange Plaza",Plot No.C/1, Mumbai- 400 001. G Block Bandra-Kurla Complex, Sandra (E), Mumb

  2. Slide 2: Investor Presentation | July 2022

    Investor Presentation | July - 2022 1

  3. Slide 3: Snapshot

    SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f

  4. Slide 4: Company Overview

    eeee Valiant 01 9000 COMPANY OVERVIEW

  5. Slide 5: Company Overview

    Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac

  6. Slide 6: Board of Directors

    Board of Directors Shri Velji K. Gogri – Chairman, Independent Director Shri Vishnu J. Sawant – Executive Director Chemical Engineer having 37 years of experience in the chemical industry, graduated Has nearly 3 decades of experience of working with Chemical Manufacturing from IIT Mumbai. A number o

  7. Slide 7: Key Milestones

    Key Milestones Expanded product range to Listed on BSE Main Board; include Chlorophenols, for Commenced Ammonolysis Received Environmental usage in intermediates in expansion at Vapi unit; clearance to enhance Pharmaceuticals, Commenced Converted into Limited Completed backward Chlorophenol capacity

  8. Slide 8: Marquee Clientele

    Marquee Clientele Shiv Corporation SALTIGO GmbH Anupam Rasayan Lanxess India Private Aarti Industries (Prop-Jenil (Lanxess Group) India Ltd. Limited Enterprise Pvt. Ltd.) Clariant Chemicals Spectrum Dyes & Supreet Chemical Kumar Organic Kisco Ltd. (India) Ltd. Chemicals Pvt. Ltd. Pvt. Ltd. Products

  9. Slide 9: Manufacturing Footprint

    Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 27,000 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •

  10. Slide 10: Key Strengths

    Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te

  11. Slide 11: Capex Projects

    Capex Projects Installed Capacity Approx. Capex Product Project Status Remarks (MT per month) (INR Mn) Commissioned Para Nitro Aniline (PNA) & Completing phase-wise • Expansion from 550 TPM to 750 TPM at Vapi plant Ortho Chloro Para Nitro 550 ~ 70 • Full capacity addition in progress Aniline (OCPNA)

  12. Slide 12: Business Overview

    seco Valiant Organics Limited 9000 BUSINESS OVERVIEW

  13. Slide 13: Chemistries And Product Basket

    Chemistries And Product Basket Ammonolysis Chlorination Key Products: Industries Served: 29% Key Products: Industries Served: • Para Nitro Aniline • Dyes • Para ChloroPhenol (PCP) • Agro Chemicals • Ortho Chloro Para Nitro Aniline • Pigments • Ortho ChloroPhenol (OCP) • Cosmetics • 2,4 Di Chlorophen

  14. Slide 14: Chlorination

    Chlorination Any reaction in which chlorine or chlorine compounds are introduced into a molecule to obtain the desired outcome Revenues (INR Mn)* is known as chlorination. 3,000 2,765 • Valiant is the only domestic player and also a global leader in Chlorophenol products with ~25% global market 2,50

  15. Slide 15: Ammonolysis

    Ammonolysis Ammonolysis is a high-pressure chemical reaction done in an auto clave where ammonia is used as a reactant. Revenues (INR Mn)* • Valiant developed Ammonolysis capabilities as a result of its two acquisitions. i.e. Abhilasha Tex Chem Pvt. Ltd. 3,500 2,917 in 2017 & Amarjyot Chemicals Ltd.

  16. Slide 16: Hydrogenation

    Hydrogenation Hydrogenation is a chemical reaction between molecular hydrogen (H2) and another compound or element, usually in the presence of a catalyst. Revenues (INR Mn)* • The company has manufacturing facilities in Jhagadia for Hydrogenation. The first unit (also named as Unit 1) 3,500 has a ca

  17. Slide 17: Other Processes

    Other Processes Acetylation Acetylation is a chemical reaction which introduces an acetyl functional group into a chemical compound. Revenues (INR Mn)* 855 • The acetylation procedure is carried out at the company’s Ahmedabad facility which has a capacity of 1,800 900 800 MTPA 700 567 530 • The key

  18. Slide 18: Industry Overview

    seco Valiant Organics Limited 9000 INDUSTRY OVERVIEW

  19. Slide 19: Industry Overview

    Industry Overview • The chemicals industry in India covers more than 80,000 commercial products. Global Chemical Market (USD Bn) • India is 6th largest manufacturer of chemicals in the world and 4th largest in Asia. Commodity Chemicals 8,000 • The Indian chemical industry was pegged at USD 178 billi

  20. Slide 20: Advantage India: Key Growth Factors

    Key Growth Factors GROWING POLICY INCREASING ADVANTAGE INDIA OPPORTUNITIES DEMAND SUPPORT INVESTMENT • Rise in demand from end-users • Supply disruption in China has • The government plans to Industries such as food processing, caused the global end-user • India’s specialty chemical introduce produc

  21. Slide 21: Financial Overview

    seco Valiant Organics Limited 9000 FINANCIAL OVERVIEW

  22. Slide 22: Historical Consolidated Income Statement

    Historical Consolidated Income Statement Particulars (INR Mn) FY19 FY20 FY21* FY22* Operational Income 6,923 6,749 7,548 11,533 Total Expenses 5,125 4,946 5,496 9,484 EBITDA 1,798 1,803 2,052 2,049 EBITDA Margins (%) 25.97% 26.71% 27.19% 17.77% Other Income 87 63 59 74 Depreciation 136 158 212 296 F

  23. Slide 23: Consolidated Balance Sheet

    Consolidated Balance Sheet Particulars (INR Mn) FY20 FY21* FY22* Particulars (INR Mn) FY20 FY21* FY22* EQUITY 4,007 5,086 6,489 Non-Current Assets 4,451 5,731 6,652 a) Equity Share Capital 121 272 272 a) Property, Plant and Equipment 2,729 4,967 5,303 b) Other Equity 3,736 4,747 5,856 b) Capital Wor

  24. Slide 24: Historical Standalone Income Statement

    Historical Standalone Income Statement Particulars (INR Mn) FY19 FY20 FY21* FY22* Revenue from Operations 6,060 5,836 5,742 9,484 Total Expenses 4,283 4,103 4,170 7,834 EBITDA 1,777 1,733 1,572 1,650 EBITDA Margins (%) 29.32% 29.69% 27.37% 17.40% Other Income 64 52 169 56 Depreciation 118 130 186 27

  25. Slide 25: Standalone Balance Sheet

    Standalone Balance Sheet Particulars (INR Mn) FY20 FY21* FY22* Particulars (INR Mn) FY20 FY21* FY22* EQUITY 3,875 5,023 6,031 Non-Current Assets 4,381 5,798 6,787 a) Equity Share Capital 121 272 272 a) Property, Plant and Equipment 2,525 4,771 5,085 b) Other Equity 3,736 4,747 5,755 b) Capital Work

  26. Slide 26: Consolidated Financial Highlights

    Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 14,000 2,300 80.00% 1,500 80.00% 2,052 2,049 11,533 70.00% 70.00% 2,000 12,000 1,798 1,803 10,000 60.00% 60.00% 1,700 7,548 50.00% 50.00% 8,000 6,923 6,749 1,400 40.00%

  27. Slide 27: Capital Market Information

    Capital Market Information Share Price up to 31st March, 2022 40% 30% 20% 10% 0% -10% -20% -30% -40% Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 Jan-22 Feb-22 Mar-22 Valiant Sensex Price Data (As on 31st March, 2022) INR Shareholding pattern (As on 31st March, 2022) Face Value 10.

  28. Slide 28: Disclaimer

    Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event

  29. Slide 29: Thank You

    eeee Valiant 01 9000 THANK YOU

Valiant Organics — Investor Presentation (July 2022) on 6ix